Cargando…
Translating co-stimulation blockade into clinical practice
Currently available information from clinical trials and open-label extensions suggest that abatacept is a good alternative to other biologicals in rheumatoid arthritis. Although at first glance the efficacy of all biologicals appears to be the same, in routine practice one might expect there to be...
Autores principales: | Westhovens, Rene, Verschueren, Patrick |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582811/ https://www.ncbi.nlm.nih.gov/pubmed/19007424 http://dx.doi.org/10.1186/ar2415 |
Ejemplares similares
-
JAK inhibition and the holy grail for pain control in early RA
por: Pazmino, Sofia, et al.
Publicado: (2022) -
Septic Arthritis Due to Staphylococcus Warneri: A Diagnostic Challenge
por: Legius, Barbara, et al.
Publicado: (2012) -
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
por: Westhovens, Rene
Publicado: (2019) -
Back to the Future With Co-Stimulation Blockade
por: Flechner, Stuart M., et al.
Publicado: (2023) -
Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis
por: Michaël, Doumen, et al.
Publicado: (2021)